Original Research Article

Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre

Cedric Peters *,1, Julie Vandewiele 1, Yolande Lievens, Marc van Eijkeren, Valérie Fonteyne, Tom Boterberg, Pieter Deseyne, Liv Veldeman, Wilfried De Neve, Chris Monten, Sabine Braems, Frédéric Duprez, Katrien Vandecasteele, Piet Ost

Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium

A R T I C L E   I N F O

Article history:
Received 8 November 2020
Revised 23 December 2020
Accepted 8 January 2021
Available online 15 January 2021

Keywords:
Bone metastases
SFRT
MFRT
Single fraction radiotherapy
Palliation
Patterns of practice
Uncomplicated

A B S T R A C T

Background: Single-fraction radiotherapy (SFRT) offers equal pain relief for uncomplicated painful bone metastases as compared to multiple-fraction radiotherapy (MFRT). Despite this evidence, the adoption of SFRT has been poor with published rates of SFRT for uncomplicated bone metastases ranging from <10% to 70%. We aimed to evaluate the adoption of SFRT and its evolution over time following the more formal endorsement of the international guidelines in our centre starting from 2013.

Materials and methods: We performed a retrospective review of fractionation schedules at our centre for painful uncomplicated bone metastases from January 2013 until December 2017. Only patients treated with $1 \times 8$ Gy (SFRT-group) or $10 \times 3$ Gy (MFRT-group) were included. We excluded other fractionation schedules, primary cancer of the bone and post-operative radiotherapy. Uncomplicated was defined as painful but not associated with impending fracture, existing fracture or existing neurological compression. Temporal trends in SFRT/MFRT usage and overall survival were investigated. We performed a lesion-based patterns of care analysis and a patient-based survival analysis. Mann-Whitney U and Chi-square test were used to assess differences between fractionation schedules and temporal trends in prescription, with Kaplan-Meier estimates used for survival analysis (p-value <0.05 considered significant).

Results: Overall, 352 patients and 594 uncomplicated bone metastases met inclusion criteria. Patient characteristics were comparable between SFRT and MFRT, except for age. Overall, SFRT was used in 92% of all metastases compared to 8% for MFRT. SFRT rates increased throughout the study period from 85% in 2013 to 95% in 2017 (p = 0.06). Re-irradiation rates were higher in patients treated with SFRT (14%) as compared to MFRT (4%) (p = 0.046). Four-week mortality and median overall survival did not differ significantly between SFRT and MFRT (17% vs 18%, p = 0.8 and 25 weeks vs 38 weeks, p = 0.97, respectively).

Conclusions: Adherence to the international guidelines for SFRT for uncomplicated bone metastasis was high and increased over time to 95%, which is the highest reported rate in literature.

© 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
standard of care. Nevertheless, international patterns of care studies indicate that longer fractionation schedules are still being over-used with reported rates of SFRT in literature ranging from 4.1% to 70.4% [10–13]. In 2013, our department decided to more formally implement the international guidelines. The goal of this paper is to evaluate the temporal trends in SFRT and MFRT for uncomplicated bone metastases over a 5-year period in a tertiary academic centre and the survival distributions of these patients.

2. Methods

2.1. Sample and data collection

We conducted a retrospective chart review of patients referred for palliative radiotherapy for uncomplicated bone metastases between January 1, 2013 and December 31, 2017. The following treatment, tumour and patient factors were included: gender, age at radiation, fractionation schedule (1 × 8 Gy or 10 × 3 Gy), patient survival status, primary tumour, irradiated anatomical site, retreatment rate, simultaneous extra-osseous meta, Karnofsky score, the Number of Risk Factors (NRF) and the Recursive Partitioning Analysis (RPA) [14,15]. Both NRF and RPA estimate prognosis. The NRF is based on three risk factors: non-breast primary cancer, metastases other than bone and KPS < 60. The RPA model includes three variables, which are the interval between primary diagnosis and radiotherapy for bone metastases, age and KPS. Furthermore we performed an in depth review of individual files and cases looking for reasons for guideline violations.

Following patients were excluded: primary cancer of the bone, patients who received postoperative radiotherapy for bone metastases and complicated metastases. Uncomplicated was defined as painful but not associated with impending fracture, existing fracture or existing spinal cord or cauda equina compression. For spinal metastases we used the spinal instability neoplastic score (SINS) [16]. A SINS between 7 and 12 was defined as an impending fracture and higher than 12 was seen as unstable. Both were viewed as complicated. Furthermore, spinal lesions with a SINS lower than 7 but with existing pathologic fracture or existing spinal cord or cauda equina compression were excluded. As were femoral lesions with more than 3 cm axial and/or 50% circumferential cortical involvement [17].

2.2. Statistical analysis

2.2.1. Patterns of care analysis

The analyses were lesion based, patients who received more than 1 course of RT were evaluated for each course separately. Descriptive statistics were applied to estimate frequencies and proportions of the SFRT and MFRT groups. Means, medians, standard deviations and ranges were reported for continuous variables. The non-parametric Mann-Whitney U and chi-square test were used to assess differences in proportions of respectively continuous and categorical variables between fractionation schedules. The chi-square test was carried out to determine temporal trends in SFRT and MFRT treatments.

2.2.2. Survival analysis

The survival analysis was patient-based. If patients were irradiated at two or more anatomical sites, only the lesion that was irradiated last was selected (594 metastases corresponding for 352 patients). To analyse differences in survival distributions, log-rank tests were performed for the following variables: fractionation schedule, NRF, RPA and a Kaplan-Meier curve was plotted for differences in survival between fractionation schedules. Two-sided P values for statistical significance were set at 0.05. All analyses were carried out using the IBM SPSS Statistics software version 25.0.

3. Results

3.1. Patterns of care analysis

The total data set consisted of 1041 bone metastases of which 594 were uncomplicated and met inclusion criteria. The eventual cohort contained 352 patients irradiated for 594 bone metastases. Table 1 gives an overview of patient and metastasis characteristics.

Overall, 91.6 percent of all metastases received a single fraction of radiotherapy in comparison to 8.4% for multiple fractions. Patient and metastasis characteristics between single and multiple fractions were comparable, except for age with patients treated with MFRT being older (table 1). The retreatment rate was higher in patients treated with SFRT (14% vs 4%; P = 0.046). SFRT adoption increased over the five study years from 85.5% in 2013 (99/116 cases) to 95.3% in 2017 (121/127) (Fig. 1, P = 0.055). In depth review of individual files and cases could not identify objective reasons for choosing MFRT over SFRT.

3.2. Survival analysis

Two hundred thirty-eight patients (68%) had died at the time of the analyses. The 4-week mortality was comparable between SFRT (17%) and MFRT (18.4%) (P = 0.8). Median overall survival was 6.5 months (95% CI 5–8) for the whole group (6.2 months for SFRT, as compared to 9.4 months for MFRT (P = 0.978)), as seen in table 2. Both the RPA and NRF model stratified patients in prognostic groups following radiotherapy. Kaplan-Meier curves showing survival for NRF and RPA models are included in Fig. 2A and B.

3.3. Discussion

From 2013 to 2017, the use of SFRT increased in our department from 85% to 95%, with a retreatment rate comparable to reported literature [5]. Our use of SFRT exceed the ones reported in literature, which range from 4.1% to 70.4% [11,13]. SFRT has several advantages over MFRT including shorter treatment time and better cost-effectiveness. Despite the published evidence showing equal pain relief rates radiation- oncologists still seem reluctant to implement SFRT. The factors influencing prescription behavior can be classified into four categories relating to patient, tumour, setting and/or oncologist [18–21]. Our retrospective review could not reveal any tumour related factors that significantly predicted choice of MFRT over SFRT for uncomplicated bone metastases. In terms of patient related factors oddly enough the MFRT-group included older patients. A reason for this could be that, despite longer overall treatment time, the need for retreatment was seen as too bothersome for older patients. A third category are the setting related factors. Our hospital is located in the Ghent metropolitan area in Belgium. Belgium is one of the most densely populated countries in the world. Ghent has a high linac density of about 1.25/100,000 population. This is on par with other high income countries [22]. In countries without a reimbursement per fractions there is a disincentive for the use of MFRT in uncomplicated bone metastases. Lievens et al. found that reimbursement modality influences the prescribed fractionation regimen in West-European radiotherapy centers. In budget and case payment financing a lower total number of fractions and lower total dose is prescribed. Longer courses tend to be more prescribed in countries where the remuneration depends on the number of treatments [12,23]. In Belgium, both SFRT and MFRT for palliation are reimbursed equally. This leads us to
believe that setting related factors are not a major issue in our case. A final category are the oncologist related factors including level of training and personal beliefs [24]. The number of patients being treated with MFRT is too low to perform meaningful statistical analyses. In depth review of individual files and cases revealed a subjective reason for choosing MFRT in a number of cases, leading us to believe that oncologist related factors are the most important driver of prescription choice in our study.

Table 1
Overview of patient and metastasis characteristics.

| Characteristics                          | All uncomplicated bone metastases (n = 594) | SFRT (n = 544; 91.6%) | MFRT (n = 50; 8.4%) | p-value |
|-----------------------------------------|---------------------------------------------|------------------------|----------------------|--------|
| Gender                                  |                                             |                        |                      |        |
| Man                                     | 342 (57.6%)                                 | 315 (57.9%)            | 27 (54%)             | 0.593  |
| Woman                                   | 252 (42.4%)                                 | 229 (42.1%)            | 23 (46%)             |        |
| Age at radiation                        |                                             |                        |                      |        |
| Mean ± standard deviation               | 64.19 ± 13.28                               | 62.95 ± 13.54          | 67.78 ± 11.16        | 0.008  |
| Median (range)                          | 66 (18–94)                                  | 64 (18–94)             | 69 (35–85)           |        |
| Primary tumour                          |                                             |                        |                      |        |
| Prostate                                | 120 (20.2%)                                 | 110 (20.2%)            | 10 (20%)             | 0.552  |
| Breast                                  | 77 (13%)                                    | 69 (12.7%)             | 8 (16%)              |        |
| Lung                                    | 153 (25.8%)                                 | 137 (25.2%)            | 16 (32%)             |        |
| Gastro-intestinal                       | 88 (14.8%)                                  | 84 (15.4%)             | 4 (8%)               |        |
| Other                                   | 156 (26.3%)                                 | 144 (26.5%)            | 12 (24%)             |        |
| Anatomical site                         |                                             |                        |                      |        |
| Axial and spinal                        | 151 (25.6%)                                 | 136 (25.2%)            | 15 (30%)             | 0.582  |
| Axial and non-spinal                    | 154 (26.1%)                                 | 144 (26.7%)            | 10 (20%)             |        |
| Non-axial                               | 263 (44.6%)                                 | 241 (44.6%)            | 22 (44%)             |        |
| Unspecified                             | 22 (3.7%)                                   | 19 (3.5%)              | 3 (6%)               |        |
| Simultaneous extra-osseous metastases   |                                             |                        |                      |        |
| No                                      | 210 (35.3%)                                 | 194 (35.6%)            | 16 (32%)             | 0.831  |
| Yes                                     | 383 (64.5%)                                 | 349 (64.2%)            | 34 (68%)             |        |
| Unknown                                 | 1 (0.2%)                                    | 1 (0.2%)               | 0                    |        |
| Needed re-irradiation                   |                                             |                        |                      |        |
| No                                      | 516 (86.9%)                                 | 468 (86%)              | 48 (96%)             | 0.046  |
| Yes                                     | 78 (13.1%)                                  | 76 (14%)               | 2 (4%)               |        |
| Karnofsky Performance Score             |                                             |                        |                      |        |
| Median (range)                          | 70 (30–100)                                 | 70 (30–100)            | 70 (50–90)           | 0.591  |
| KPS < 70                                | 141 (33.73%)                                | 129 (33.86%)           | 12 (32.43%)          |        |
| KPS ≥ 70                                | 277 (66.27%)                                | 252 (66.14%)           | 25 (67.57%)          |        |

*for 176 patients no KPS.

Fig. 1. Graph showing the adoption of SFRT over the five study years.

Both RPA and NRF models are suggested as survival prediction tools to objectify patient prognosis in patients with spinal bone metastases and with general metastatic cancer, respectively. In the current analysis, we were able to confirm the discriminative power of these models. Four-week mortality did not differ between treatment groups which leads us to believe that a significant portion of patients with the worst prognosis did not receive SFRT. Seven patients in the MFRT-group died within 4 weeks of the
end of their treatment. This might mean that they did not live long enough to enjoy any treatment effect.

There are several limitations of our study. The first being its retrospective nature. This meant there was no standardised way of assessing patients’ pain response. As such pain response wasn’t reported. The retrospective nature also limited our ability to thoroughly examine prescription behavior. Prospectively collected data could have included questionnaires that would help us understand the rationale of choosing MFRT in uncomplicated bone metastases. Because of the high uptake of SFRT in our centre the MFRT groups consisted of only 50 metastases. This limited our ability to find factors that drove further prescription of longer courses. The past few

---

**Table 2**

Univariate survival analysis.

| Characteristics          | Number of patients (n = 352) | Median overall survival (95% CI) | P-value |
|--------------------------|------------------------------|---------------------------------|---------|
| **Fractionation schedule** |                              |                                 |         |
| Number of evaluable patients | 348                         |                                 | 0.978   |
| SFRT                      | 310 (89.1%)                  | 6.2 months (5–7.4)              |         |
| MFRT                      | 38 (10.9%)                   | 9.4 months (6–12.9)             |         |
| **RPA**                  |                              |                                 |         |
| All patients              |                              |                                 |         |
| Number of evaluable patients | 298                         |                                 | <0.001  |
| Class 1                   | 43 (14.4%)                   | 29.5 months (7.2–51.75)         |         |
| Class 2                   | 200 (67.1%)                  | 4.8 months (3.18–6.4)           |         |
| Class 3                   | 55 (18.5%)                   | 3.65 months (0.1–7.21)          |         |
| **NRF**                  |                              |                                 | <0.001  |
| Number of evaluable patients | 241                         |                                 |         |
| 0 risk factors            | 14 (5.8%)                    | Not reached                     |         |
| 1 risk factor             | 54 (22.4%)                   | 11.1 months (0–24.58)           |         |
| 2 risk factors            | 118 (49%)                    | 4.04 months (1.32–6.75)         |         |
| 3 risk factors            | 55 (22.8%)                   | 2.23 months (1.13–3.33)         |         |
| **Died within 4 weeks of RT** |                              |                                 | 0.825   |
| All patients              |                              |                                 |         |
| Number of evaluable patients | 350                         |                                 |         |
| Yes                       | 60 (17.1%)                   |                                 |         |
| No                        | 290 (82.9%)                  |                                 |         |
| SFRT                      |                              |                                 |         |
| Number of evaluable patients | 312                         |                                 |         |
| Yes                       | 53 (17%)                     |                                 |         |
| No                        | 259 (83%)                    |                                 |         |
| MFRT                      |                              |                                 |         |
| Number of evaluable patients | 38                          |                                 |         |
| Yes                       | 7 (18.4%)                    |                                 |         |
| No                        | 31 (81.6%)                   |                                 |         |

*RPA: recursive partitioning analysis index; NRF: number of risk factors. Log-rank test was used.

---

Fig. 2. (A) Kaplan-Meier reporting time between radiotherapy and death stratified per NRF. (B) Kaplan-Meier reporting time between radiotherapy and death stratified per RPA.
years have seen the rise of local treatment for oligometastatic disease namely SBRT [25–27]. Our review only looked at 1 × 8Gy and 10 × 3Gy schedules. As such any other schedule, including for oligometastatic disease, were excluded.

4. Conclusion

Adherence to the international guidelines for SFRT for uncomplicated bone metastasis was high and increased over time to 95%, which is the highest reported rate in literature.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Chow E, Harris K, Fan C, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007;25(11):1423–36.
[2] Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012;24(2):112–24.
[3] Falkner U, Järhult J, Wersäll P, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003;42(5–6):620–33.
[4] Berk L. Prospective trials for the radiotherapeutic treatment of bone metastases. Am J Hosp Palliat Care 1995;12(4):24–8.
[5] Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 2018;126(3):547–57.
[6] Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters Jr RS, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009;12(5):417–26.
[7] Fairchild A, Barnes E, Ghosh S, Reis-Josef E, Roos D, Hartsell W, et al. International patterns of practice in radiotherapy for painful bone metastases: evidence-based practice?. Int J Radiat Oncol Biol Phys 2009;75(5):1503–10.
[8] Foro Arnalot P, Fontanals AV, Galceran JC, Lynd F, Latiesas SS, de Dios NR, et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 2008;89(2):150–5.
[9] Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79(4):965–76.
[10] Rutter CE, Yu JR, Wilson LD, Park HS. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys 2015;91(3):548–55.
[11] Tiwana MS, Barnes M, Yurkowski E, Roden K, Olson RA. Incidence and treatment patterns of complicated bone metastases in a population-based radiotherapy program. Radiat Oncol 2016;11(3):552–6.
[12] McDonald R, Chow E, Lam H, Rowbottom L, Soliman H. International patterns of practice in radiotherapy for bone metastases: A review of the literature. J Bone Oncol 2014;3(3–4):96–102.
[13] Petrushevski AN, Gabriel GS, Hanna TP, Allen S, Allison RW, Barton MB. Factors affecting the use of single-fraction radiotherapy for the palliation of bone metastases in Australia. Clin Oncol (R Coll Radiol) 2015;27(4):205–12.
[14] Chow E, Abdollahi M, Panzarella T, Harris K, Bezjak A, Warde P, et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol 2008;26(36):5863–9.
[15] Chao ST, Koyfman SA, Woody N, Angelov L, Soeder SL, Reddy CA, et al. Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys 2012;82(5):1738–43. https://doi.org/10.1016/j.ijrobp.2011.02.019.
[16] Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010;35(22):E1221-9.
[17] Harrington KD. Impending pathologic fractures from metastatic malignancy: evaluation and management. Instr Course Lect 1986;35:357–81.
[18] Ashworth A, Kong W, Chow E, Mackillop WJ. Fractionation of Palliative Radiation Therapy For Bone Metastases in Ontario: do practice guidelines guide practice?. Int J Radiat Oncol Biol Phys 2016;94(1):31–9.
[19] van der Linden Y, Roos D, Lutz S, Fairchild A. International variations in radiation fractionation for bone metastases: geographic borders define practice patterns?. Clin Oncol (R Coll Radiol) 2009;21(9):655–8.
[20] Bradley NM, Husted J, Sey MS, Husain AF, Sinclair E, Harris K, et al. Review of patterns of practice and patients’ preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer 2007;15(4):373–85.
[21] Popovic M, den Hartogh M, Zhang L, Poorn M, Lam H, Bedard G, et al. Review of international patterns of practice for the treatment of painful bone metastases with palliative radiotherapy from 1993 to 2013. Radiother Oncol 2014;111(1):11–7.
[22] Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 2005;75(3):349–54.
[23] Lievens Y, Van den Bogaert W, Rijnders A, Ketke W, Kesteloot K. Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system?. Radiother Oncol 2000;56(3):289–95.
[24] Crellin AM, Marks A, Maher EJ. Why don’t British radiotherapists give single fractions of radiotherapy for bone metastases?. Clin Oncol (R Coll Radiol) 1989;1(2):63–6.

[25] Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393(10185):2051–8.

[26] Gomez DR, Tang C, Zhang J, Blumenschein Jr GR, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 2019;37(18):1538–45.

[27] Ost P, Beynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36(5):446–53.